1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This grant may no longer be accepting applications.
The description indicates applications may be closed. Check the funder's website to confirm availability before applying.
Visit funder's website →Glenn Foundation for Medical Research Postdoctoral Fellowships in Aging Research is sponsored by American Federation for Aging Research (AFAR) and Glenn Foundation for Medical Research. This fellowship supports postdoctoral scientists conducting research in aging. AFAR's grant programs are central to its mission to support and advance healthy aging through biomedical research.
Get alerted about grants like this
Save a search for “American Federation for Aging Research (AFAR) and Glenn Foundation for Medical Research” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Glenn Foundation for Medical Research Postdoctoral Fellowships in Aging Research - American Federation for Aging Research Ask the Expert Interviews 2025 Grantee Spotlight Interviews Dorothy Dillon Eweson Lecture Series Administrative Guidelines Things to Consider When Applying Funding Updates Newsletter by funding Grant Programs and Fellowships by guiding studies such as the FAST Initiative , the SuperAgers Initiative , and the TAME Trial by supporting the infrastructure of three NIA Initiatives and leading the Amplifying Geroscience Initiative .
Top Breakthroughs driven by AFAR Experts Delaying Disease by Targeting Aging Saving Costs by Extending Healthspan What are the Hallmarks of Aging? What is the Longevity Dividend? Why AFAR, Why Aging Research Clarence Pearson Fellowship NIA Infrastructure Support The SuperAgers Initiative Amplifying Geroscience Initiative Breakthroughs by AFAR Experts What are the Hallmarks of Aging?
What is the Longevity Dividend? Ask the Expert Interviews What is Geroscience?
2025 AFAR Awards of Distinction Glenn Foundation for Medical Research Postdoctoral Fellowships in Aging Research Application Procedures and Timeline This program was developed to provide support for postdoctoral fellows (MD, MD/PhD and PhD) who specifically direct their research towards basic aging mechanisms and/or translational findings that have direct benefits to human aging and healthspan .
Postdoctoral fellows at all levels of training are eligible. Up to twelve one-year fellowships of $80,000 will be awarded in 2026.
The Glenn Foundation for Medical Research (GFMR), in partnership with the American Federation for Aging Research (AFAR), created the Glenn Foundation for Medical Research Postdoctoral Fellowships in Aging Research to encourage and further the careers of postdoctoral fellows who are conducting research in the basic biology of aging, as well as translating advances in basic research from the laboratory to the clinic .
The award is intended to provide significant research and training support to permit these postdoctoral fellows to become established in the field of aging.
The GFMR Postdoctoral Fellowship program supports research projects concerned with understanding the basic mechanisms of aging as well as projects that have direct relevance to human aging if they show the potential to lead to clinically relevant strategies that address human aging and healthspan.
Projects investigating age-related diseases will be considered, but only if approached from the point of view of how basic aging processes may lead to these outcomes. Projects concerning mechanisms underlying common geriatric functional disorders such as frailty will also be considered.
Projects that are strictly clinical in nature such as the diagnosis and treatment of disease, health outcomes, or the social context of aging are not eligible. It is anticipated that up to 12 one-year grants will be awarded in 2026.
The grant is $80,000, of which a minimum of $62,652 (*see note below) is to be used for salary and the remainder to be used for allowable expenses (research supplies, equipment, health insurance, travel to scientific meetings where the Fellow is presenting his/her biology of aging research, and relevant research and educational training). Funds for indirect costs or overhead are not allowed.
* The applicant’s salary/stipend must equal or exceed NIH pay scale for postdoctoral fellowships, appropriate to the level of training, https://www. niaid. nih.
gov/grants-contracts/salary-cap-stipends . Thus, if the NIH stipend minimum for the corresponding level of experience exceeds $62,652, additional award funds may be taken as salary to meet the NIH standard. Recipients of this award are expected to attend the combined Glenn AFAR Grantee Conference and Glenn Workshop on the Biology of Aging; funds will be allocated from the grant for this purpose.
The goal of the meeting is to promote scientific and personal exchanges among recent AFAR grantees and experts in aging research. If awarded, GFMR Postdoctoral Fellows may be eligible to apply for a second year of funding though the GFMR Postdoctoral Fellowship Continuation award . The applicant must be a postdoctoral fellow (MD and/or PhD degree or equivalent) by the deadline date of the LOI submission, January 27, 2026.
The proposed research must be conducted at a qualified not-for-profit setting in the United States. Individuals who are employees in the NIH Intramural program are not eligible. Postdoctoral fellows in laboratories that receive support as part of a Paul F.
Glenn Center for Biology of Aging Research are not eligible to apply. Applicants who have received more than 5 years of postdoctoral training at the time of the start of the award must provide a justification for the additional training period.
Former GFMR postdoctoral fellowship awardees are not eligible to apply, but may be eligible to apply for GFMR postdoctoral fellowship Continuation Awards Fellows may not hold any concurrent funding for the same research project. We welcome applicants from all groups including those underrepresented in the biomedical sciences.
The following criteria are used to determine the merit of an application: Qualifications of the applicant Quality of the proposed research (*see note below) Proposed career development plan, and training opportunities for the applicant Excellence of the research environment Likelihood that the applicant will pursue a career in aging research Mentor's strength and qualifications to guide the applicant's research and career planning * We recognize that most applicants’ postdoctoral projects will be multi-year projects.
As such, the applicant should describe the overall project but indicate the scope of the work that is being proposed for the year to be funded by a Fellowship if awarded. Application Procedures and Timeline Please refer to the Letter of Intent instructions . Incomplete or late submissions will not be considered.
All Letters of Intent must uploaded here . The Letters of Intent will be reviewed by a committee. A subset of applicants will be invited to submit a full application which will be reviewed by a Selection Committee.
The Selection Committee’s recommendations will be presented to AFAR and GFMR which will make final funding decisions. Please review this link which includes suggestions for submitting an LOI or application to AFAR. Click here for our Frequently Asked Questions page.
If you are using animals in your research, we strongly encourage you to review Guidelines for Aging Rodent Research . AFAR will not provide reviewer critiques to any applicants at any review level.
LOI deadline: January 27, 2026 Results of LOI review: Mid-April 2026 Deadline for full application: Late May 2026 Award Announcements: Late June 2026 Award Start Date: July 1, 2026 Investigators will be required to submit narrative and financial reports within three months following the end date of the award. Glenn Foundation for Medical Research Founded by Paul F.
Glenn in 1965, the mission of the Glenn Foundation For Medical Research is to extend the healthy years of life through research on mechanisms of biology that govern normal human aging and its related physiological decline, with the objective of translating research into interventions that will extend healthspan with lifespan.
Funding Updates Newsletter McKnight Brain Research Foundation Innovator Awards in Cognitive Aging and Memory Loss Who is eligible: Independent Assistant and Associate Professors Research area: Cognitive Aging and Memory Loss Amount of award: $750,000 Number of awards given: Two Deadline for Letter of Intent: April 15, 2026 Hevolution Foundation Scientific Conferences Fund Who is eligible: Non-profit organizations, public and private universities, colleges, laboratories and government agencies in North America (Canada, United States of America, and Mexico), the United Kingdom, and countries in the European Union Amount of award: Up to $10,000 per meeting Deadline: January 31, April 30, July 31, October 31 Diana Jacobs Kalman/AFAR Graduate Student Awards in Geroscience Who is Eligible: MD, DO, PhD, or combined degree students who have completed at least two years by October 1, 2026 Research Area: Geroscience and the Biology of aging Nomination Deadline: May 8, 2026 AFAR Grants for Junior Faculty and Glenn Foundation for Medical Research (GFMR) Grants for Junior Faculty Who is eligible: Independent Early Stage Investigators Research area: Biology of aging Amount of award: $160,000 Award period: 1 or 2 years Number of awards given: Approximately 10 Deadline for LOI: The deadline has passed for 2026 The Sagol Network GerOmic Award for Junior Faculty Who is eligible: Independent Junior Faculty Research area: Aging-related -omics research Amount of award: $160,000 Award period: 1 or 2 years Number of awards given: 1 Letter of Intent Deadline: The deadline has passed for 2026 2025 Glenn Foundation for Medical Research Postdoctoral Fellowship Continuation Awards Who is Eligible: Current or former GFMR Postdoctoral Fellows in Aging Research Research Focus: Basic and translational research that builds on early discoveries that show translational potential for clinical relevant strategies Award Amount: $80,000 (a minimum of $62,652 is to be used for salary and the remainder to be used for allowable expenses) Letter of Intent Deadline : The deadline has passed for 2026 Glenn Foundation for Medical Research (GFMR) Discovery Award Who is Eligible: Full-time faculty at the rank of Assistant Professor or higher Research Focus: Biology of aging Letter of Intent Deadline: The deadline has passed for 2026 Medical Student Training in Aging Research (MSTAR) Program Who is Eligible: Any allopathic or osteopathic medical student in good standing, who will have successfully completed one year of medical school at a U.S. institution by June 2026.
Interested students should be in touch directly with the National Training Centers to determine their eligibility and program deadline.
Small Research Grant Program for the Next Generation of Researchers in Alzheimer's Disease (R03) Who is Eligible: Early stage investigators in AD/ADRD research and established researchers who are not currently doing AD/ADRD research Research area: Alzheimer’s Disease and Alzheimer’s Disease Related Dementias Awards Given: approximately 12 Deadlines: February 16, June 16, and October 16.
According to the current listing, eligibility includes: Postdoctoral Fellows. Confirm the full requirements in the official notice before applying.
Glenn Foundation for Medical Research Postdoctoral Fellowships in Aging Research is funded by American Federation for Aging Research (AFAR) and Glenn Foundation for Medical Research. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
DARPA BTO pre-released four FY26 SBIR/STTR topics on April 30, 2026, with proposals due June 3. Two topics — SWiFT and EXPOSITION — offer Direct-to-Phase-II awards up to $1.5M, bypassing the standard Phase I gate. Here is what each topic is actually solving, why the DP2 structure matters, and how small biotech, surgical robotics, and battlefield-medicine teams should decide whether to compete.
Read articleOn June 3, 2026, four DARPA Biological Technologies Office SBIR topics close simultaneously — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Combined Phase I plus Phase II potential exceeds $6 million per company, and together they sketch a coherent strategy of distributed, autonomous, dual-species combat casualty care that depends on small businesses, not primes, to actually build.
Read articleThe BARK program funds dual-use medical products for warfighters and military working dogs — tourniquets, sensors, drug delivery, and CBRN countermeasures. Proposals close June 3, 2026.
Read article